navify Mutation Profiler: Precise and Robust Tertiary Analysis of CGP Results, Featuring the Pioneering Pan-Cancer HRD Signature Score

navify Mutation Profiler* (MP) supports precision oncology by converting complex NGS data into relevant insights. With up-to-date regional guidelines, approvals, and clinical trials, it offers a secure, cloud-based solution for variant interpretation and delivers comprehensive customizable or standardized reports. navify MP is powered by expert-curated content for 19 solid tumor types and 48 hematological malignancies, encompassing >33,000 curated variants, >12,250 biomarker profiles, and >1,000,000 biomarker/disease associations. In conjunction with AVENIO Tumor Tissue CGP kits, navify MP provides functionality to interpret and report the newpan-tumor HRD signature (HRDsig) score. Leveraging a powerful algorithm trained on Foundation Medicine’s vast pan-tumor genomic database with over 100 unique genomic features, HRDsig distinguishes itself from all other HRD scores on the market.
*For Research Use Only in the US.